Review on Icariin as A Novel Medicaments to Confront Ovarian Cancer
Ovarian cancer is described as one of the most common types of cancer and the leading cause of cancer-related deaths due to the high aggressiveness of this malignancy. However, the current therapeutically strategies failed to confront ovarian cancer or are accompanied by significant adverse effects leading to the recurrence of the disease and/or affecting the quality of life of survivors. On the other hand, ovarian cancer is recognized as a heterogenous disorder that is specified by alteration in a variety of molecular and cellular markers. Thereby, researchers are keen to find a novel therapeutical strategy representing high efficacy and safety, as well as be able to modulate altered biomolecules and signaling pathways. Icariin is a phytoestrogen with desired properties that are suggested for several chronic complications, particularly different types of cancer. The aim of the present study was to reveal the ameliorative characteristics of icariin and then discuss the antitumoral activities of this phytochemical against ovarian cancer with an emphasis on the modified molecular signaling pathways
- حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران میشود.
- پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانههای چاپی و دیجیتال را به کاربر نمیدهد.